On01910

Manufactured by Selleck Chemicals

Sourced in United States

ON01910 is a chemical compound used in laboratory settings. It serves as a core component in various research and testing applications. The detailed technical specifications and intended uses of this product are not available for disclosure.

Automatically generated - may contain errors

Lab products found in correlation

5 protocols using on01910

Inhibition of cell death pathways

Check if the same lab product or an alternative is used in the 5 most similar protocols

PLK1 inhibitors: BI6727 and ON01910 were obtained from Selleck Chemicals (Selleckchem, Houston, TX, USA; cat. #S2235 and cat. #S1362). Caspase inhibitor: z-VAD-fmk was purchased from Biomol Research Laboratories (Plymouth Meeting, PA, USA; cat. #BML-P416-0001). Necropotosis inhibitor: necrostatin-1 was purchased from Sigma-Aldrich (cat. #N9037).

Mao Y., Tamura T., Yuki Y., Abe D., Tamada Y., Imoto S., Tanaka H., Homma H., Tagawa K., Miyano S, & Okazawa H. (2016). The hnRNP-Htt axis regulates necrotic cell death induced by transcriptional repression through impaired RNA splicing. Cell Death & Disease, 7(4), e2207-.

+ Open protocol

+ Expand

Inhibition of PLK1 Reduces Cell Viability

Check if the same lab product or an alternative is used in the 5 most similar protocols

Cells were treated with four small molecule inhibitors directed against PLK1, GSK461364 (Axon Medchem), BI6727 (Axon Medchem), ON-01910 (Selleckchem) and HMN-214 (Selleckchem), all dissolved in DMSO. Cells were treated with concentrations ranging from 0 till 12 μM, where concentrations of DMSO were always below 0.1%. After 72 hours of incubation the effects on cell viability were measured as described above.

de Boer D.V., Martens-de Kemp S.R., Buijze M., Stigter-van Walsum M., Bloemena E., Dietrich R., Leemans C.R., van Beusechem V.W., Braakhuis B.J, & Brakenhoff R.H. (2017). Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck. Oncotarget, 8(58), 97928-97940.

+ Open protocol

+ Expand

Dose response optimization of PLK1 inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols

Small molecule PLK1 inhibitors (drugs), BI 2536, BI 6727, HMN-214, and ON01910, used for dose response optimization studies, were all purchased from Selleck Chemicals, and stored at −80°C. Optimization experiments with inhibitor leads were carried out in a similar fashion to screening experiments, but in 24 well plates with 200 ng pGL3.0 or pEGFP-C1 (Clontech; an eGFP expression plasmid with a CMV promoter) plasmid DNA/well, at various concentrations of each inhibitor with various polymers (10:1 w/w 1,4C-1,4Bis or 1:1 w/w PEI) and cell lines (PC3-PSMA or MB49, both seeded at 50,000 cells/well). The Entinostat used in the inhibitor combination transfections was kindly provided by Syndax Pharmaceuticals of Waltham, MA through an agreement with the Cancer Therapeutics Evaluation Program (CTEP) at NIH. The final DMSO concentration in a given well was kept constant at 0.5% in all experiments with inhibitor combinations.

Christensen M.D., Elmer J.J., Eaton S., Gonzalez-Malerva L., LaBaer J, & Rege K. (2015). Kinome-Level Screening Identifies Inhibition of Polo-Like Kinase-1 (PLK1) as a Target for Enhancing Non-Viral Transgene Expression. Journal of controlled release : official journal of the Controlled Release Society, 204, 20-29.

+ Open protocol

+ Expand

Detailed Chemical Inhibitor Library

Check if the same lab product or an alternative is used in the 5 most similar protocols

Chemical compounds including AZD1775, THZ1 2HCl, TWS119, PD-0332991, RO-3306, PD0166285, LJI308, ON-01910, LY2606368, MK-2206 2HCl, AMN-107, VE-821, KU55933, KU-57788, NSC 119875, and NSC 125973 were acquired from Selleck. Protein kinase inhibitor 1 hydrochloride was sourced from MCE. Supplementary Table 3 provides IC50 values for 15 inhibitors obtained from cell-free assays, including information on their target specificity, potential secondary targets, as well as their commercial names and catalog numbers. To supply nucleotide precursors, a mix of four dNTPs (50 uM each) was added for 48 h. The dNTP set from Sigma-Aldrich (DNTP100-1KT) consists of four separate 0.25 mL tubes, each containing 100 mM aqueous solutions of deoxyribonucleotides: deoxyribose adenosine triphosphate, deoxyribose cytidine triphosphate, deoxyribose guanosine triphosphate, and deoxyribose thymidine triphosphate.

Yang X., Hu X., Yin J., Li W., Fu Y., Yang B., Fan J., Lu F., Qin T., Kang X., Zhuang X., Li F., Xiao R., Shi T., Song K., Li J., Chen G, & Sun C. (2024). Comprehensive multi-omics analysis reveals WEE1 as a synergistic lethal target with hyperthermia through CDK1 super-activation. Nature Communications, 15, 2089.

+ Open protocol

+ Expand

Regulation of HBV Replication by PLK1

Check if the same lab product or an alternative is used in the 5 most similar protocols

All chemicals were purchased from Sigma Aldrich unless otherwise specified. PLK1 inhibitors (BI-2536, BI 6727, MLN 0905 and ON 01910) were from Selleckchem. Polyclonal HBc^{(19 (link))}, and commercially available HBc antibodies were used for immunofluorescent staining and immunoblots. Rabbit polyclonal anti-HBc was from Dako (B0586) or Abcam (ab140243) and monoclonal anti-HBc from Abcam (ab8637; Clone C1). PLK1 antibodies used: rabbit polyclonal (ab21738) for detection of phospho-PLK1-S₁₃₇ in WB and IF; rabbit monoclonal (ab115095) for detection of phospho-PLK1-T₂₁₀ in WB and IF, and rabbit polyclonal (ab109777) for detection of PLK1. Small interfering RNA (SmartPool or sequence designed) were purchased from Dharmacon, transfected into dHepaRG or PHH using Darmafect-1 reagent, following manufacturer’s instructions. Tenofovir (TFV) and HBV capsid assembly inhibitors Bay41-4109^{(20 (link))} and AT130^{(21 (link))} were kindly provided by Gilead Sciences and Novira Pharmaceutics, respectively. IFN-α (i.e. Roferon) was from Hoffmann-La-Roche.

Diab A.M., Foca A., Fusil F., Lahlali T., Jalaguier P., Amirache F., N’Guyen L., Isorce N., Cosset F.L., Zoulim F., Andrisani O.M, & Durantel D. (2017). Polo-like-kinase 1 is a proviral host-factor for hepatitis B virus replication. Hepatology (Baltimore, Md.), 66(6), 1750-1765.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!